Update shared on 22 Nov 2025
Fair value Decreased 0.48%Analysts have modestly lowered their price target for SCHOTT Pharma KGaA from €29.33 to €29.19, citing slight reductions in anticipated revenue growth and profit margins, as well as a higher discount rate used in their updated valuation models.
What's in the News
- Christian Mias appointed as CEO of SCHOTT Pharma KGaA. He will begin his role on May 1, 2026 (Key Developments).
- Outgoing CEO Andreas Reisse will retire in April 2026, supporting a seamless leadership transition (Key Developments).
- Christian Mias brings over 20 years of management experience, including leadership roles within SCHOTT Group in Brazil, the United States, and the pharmaceutical sector (Key Developments).
- Since 2016, Christian Mias has served in executive positions at SCHOTT, focusing on process optimization and profitable growth (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has decreased modestly from €29.33 to €29.19.
- Discount Rate has increased from 5.23% to 5.81%.
- Revenue Growth forecast has declined from 9.81% to 9.17%.
- Net Profit Margin projection has moved slightly lower from 17.49% to 17.38%.
- Future P/E ratio estimate has gone up from 23.29x to 23.67x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.